Optimize Clinical Diabetes Management with AI Technology
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.
In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.
Part 2: Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients
A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series.
The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.
Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature will be a 3-part series.
In Part 1: Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs.
SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.
Read More »The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors
Is the risk as substantial as was initially reported?
Read More »Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer
The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss.
Read More »The Relationship Between Aerobic Exercise Capacity and Cardiac Dysfunction In T2D
In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.
Read More »Possible Link Connecting COVID-19 and New-Onset Diabetes
CoviDIAB Registry will explore why COVID-19 can increase complications in people with pre-existing diabetes, and may also be driving new cases.
Read More »Adding An SGLT-2 Earlier To A Treatment Plan Yields Positive A1c Levels
If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.
Read More »